18.10.2024 | Tracker
Product Launch Tracker: HCPs celebrated the FDA’s approval of FluMist
During September 2024, CREATION.co tracked the global conversations of 1,708 healthcare professionals (HCPs) who posted 2,704 times about the launches and approvals of new products.
On 20 September, the FDA approved AstraZeneca’s FluMist Nasal Spray for at-home administration. 88 HCPs reacted to the news by sharing about the approval. Since the vaccine does not need to be administered by a healthcare professional, 48 HCPs celebrated this highlighting its ease and convenience alongside noting that the nasal spray is also accessible for ‘needle-shy people.’
🔥BREAKING: Nasal Flu vaccine!
"The FDA on Friday authorized at-home use of FluMist, opening the door for needle-shy people to have easy access to a nasal spray vaccine that is potentially lifesaving.
By @AstraZeneca 👏 https://t.co/8ht7GyMtu6
— Harry Spoelstra (@HarrySpoelstra) September 20, 2024
Big win for public health today with the @US_FDA approval of the nasal flu vaccine Flumist for at-home use!
For those 2 to 49 years old, this option has long existed, but now you can self administer it at home with a Rx.
Access, ease, convenience! pic.twitter.com/ET65EzVfsh
— Dr. Vin Gupta (@VinGuptaMD) September 20, 2024
Approval of Osimertinib
On 25 September, the FDA expanded the approval of Osimertinib following the results of the LAURA trial. 60 HCPs shared 70 times about the approval on X. Medical Oncologist, Antonio Calles, highlighted its ‘massive benefit’ for patients with locally advanced stage III EGFR+ non-small cell lung cancer.
🔥🚨 @OncoAlert Hot off the press.
As expected, @US_FDA approves #Osimertinib for #locallyadvanced #EGFR+ #NSCLC following concurrent or sequential #Chemoradiation.
Approval based on #Laura trial:
⬆️#mPFS 39.1 (Osi) vs 5.6 months (placebo). HR 0.16
👇🏼https://t.co/J1bZQmQPlO pic.twitter.com/qNdBwrwSLx
— Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation (@RManochakian) September 25, 2024
🥁 It’s now FDA Approved 👍
💊 Massive benefit from osimertinib in this unmet medical indication. 📈 https://t.co/tmh6AoUs0s https://t.co/4rBUO8F53h— Dr. Antonio Calles 🫁🚭 (@Tony_Calles) September 27, 2024
Excitement for the approval of Cobenfy
On 27 September, the FDA approved Bristol Myers Squibb’s, first-in-class treatment of schizophrenia, Cobenfy. 68 HCPs posted about the approval of Cobenfy in 72 posts. Psychiatrist, Prakash Masand, expressed his excitement towards the approval and stated that it is ‘a truly innovative mechanism of action.’
Exciting news for patients, caregivers, and clinicians! I'm excited to see that the FDA has approved #KarXT(#Cobenfy) as the first non-antipsychotic for the treatment of schizophrenia in adults.
Cobenfy has a truly innovative mechanism of action, something we have not seen in…— Prakash Masand (@PMasand) September 27, 2024
The three most shared stories from HCPs discussing product launches in September were:
- An FDA Breakthrough Device Designation for Neuralink’s Blindsight device – 41 posts.
- An FDA press release announcing the approval of FluMist Nasal Spray Influenza Vaccine for Self- or Caregiver-Administration – 37 posts.
- An FDA press release announcing the approval of pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma (MPM) – 37 posts.
Each month, CREATION.co tracks the HCP conversation relating to new product launches.
You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area-specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology
- CREATION Pinpoint® listened to the discussions amongst online HCPs of pharmaceutical product launches and drug approvals between 1 September and 30 September 2024.
- The data included mentions of drug approvals by the FDA, EMA, MHRA, NICE, and CHMP, as well as HCPs’ use of the phrase ‘drug approval’ in their posts.
- Between 1 and 30 September 2024, 1,708 online HCPs worldwide made 2,704 references to new pharmaceutical product launches and drug approvals.